Patent: 10,231,975
✉ Email this page to a colleague
Summary for Patent: 10,231,975
Title: | Use of aerosolized levofloxacin for treating cystic fibrosis |
Abstract: | Methods for treating cystic fibrosis. The method includes administering to a human in need thereof an aerosol solution comprising levofloxacin or ofloxacin and a divalent or trivalent cation. More particularly, the method includes administering the aerosol solution to a human having a pulmonary infection comprising P. aeruginosa. |
Inventor(s): | Loutit; Jeffery S. (Los Altos, CA), Morgan; Elizabeth E. (Escondido, CA), Dudley; Michael N. (San Diego, CA), Griffith; David C. (San Marcos, CA), Lomovskaya; Olga (Mountain View, CA) |
Assignee: | Horizon Orphan LLC (Lake Forest, IL) |
Application Number: | 15/623,168 |
Patent Claims: | see list of patent claims |
Details for Patent 10,231,975
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Organon Usa Inc., A Subsidiary Of Merck & Co., Inc. | COTAZYM | pancrelipase | Capsule, Delayed Release | 020580 | 12/09/1996 | ⤷ Try a Trial | 2029-09-04 |
Abbvie Inc. | CREON | pancrelipase | Capsule, Delayed Release | 020725 | 04/30/2009 | ⤷ Try a Trial | 2029-09-04 |
Abbvie Inc. | CREON | pancrelipase | Capsule, Delayed Release | 020725 | 06/10/2011 | ⤷ Try a Trial | 2029-09-04 |
Abbvie Inc. | CREON | pancrelipase | Capsule, Delayed Release | 020725 | 03/14/2013 | ⤷ Try a Trial | 2029-09-04 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |